Long-Term Debt: Arcus Bio (RCUS)

Brandmark of Arcus Corp (RCUS)

The stock price chart for RCUS demonstrates the growth of this company, which develops treatments to stimulate immune response against tumors. Management is successfully developing its scientific base and attracting investment through strategic alliances. Despite significant testing costs, which amount to 0.10, the financial deficit is mitigated by partner payments. The overall success of the business is based on the results of TIGIT projects and the support of Gilead.

RCUS (Arcus Bio) Company Long-Term Debt history from 07/04/2022 to 10/31/2026

Arcus Bio - analytical breakdowns and key metrics (RCUS)

- current quotes and average value forecast:
Stock Quotes arcusbio.com|RCUS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Arcus Biosciences|RCUS - Total Company Value
- book capitalization data:
Net Assets per Single Share Arcus Biosciences|RCUS - Company Book Value|Market-to-Book Ratio arcusbio.com|RCUS - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Arcus Biosciences, Inc.|RCUS - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Arcus Corp|RCUS - Company Total Debt|Debt to Net Assets Ratio Arcus Biosciences|RCUS - Company Long-Term Debts|Short-Term Debt Volume Arcus Biosciences|Quick Liquidity Indicator arcusbio.com
- net income and valuation multiples indicators:
RCUS - Company Net Income
Fundamental company valuation:arcusbio.com
Core merchandise of Arcus Biosciences

The investment attractiveness of Arcus Biosciences, Inc. (RCUS) is reflected in the company's long-term debt chart, where the absence of excessive leverage confirms the effectiveness of funding research and development through partner payments. This indicator aggregates all obligations with maturities exceeding one year, allowing investors to assess the stability of the debt profile and the issuer's ability to scale immunotherapy projects without a critical debt burden.

Who Arcus Biosciences, Inc. competes with

IBRX - Company Long-Term Liabilities|IMCR - Company Long-Term Debt|Long-Term Debt Janux Therapeutics Inc|Zymeworks Corp (ZYME) - Company Long-Term Debt|TNGX (Tango Therapeutics Corp) - Company Long-Term Debt|Company Long-Term Debt Iovance Biotherapeutics|Long-Term Debt immatics.com IMTX|Company Long-Term Debts XNCR|Compass Therapeutics Inc (CMPX) - Long-Term Indebtedness|Replimune Corp - Company Long-Term Liabilities|Lyell Pharma (LYEL) - Long-Term Debt|IPHA: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings PYXS (Pyxis Oncology, Inc.)|CGEN: Company Long-Term Debts|IOBT - Long-Term Debt Volume|Company Long-Term Debt Sutro Bio|Company Long-Term Liabilities MiNK Therapeutics, Inc (INKT)|Company Long-Term Debt Werewolf Therapeutics (HOWL)|Company Long-Term Liabilities immixbio.com IMMX|ALX Oncology Holdings - Company Long-Term Liabilities|Company Long-Term Debts cuebiopharma.com CUE|PDSB - Company Long-Term Debt|SONN (Sonnet BioTherapeutics) - Company Long-Term Indebtedness|MAIA Biotechnology (MAIA) - Company Long-Term Debt|Long-Term Debt liminatuspharma.com (LIMN)|Company Long-Term Liabilities LVTX|NXTC - Long-Term Indebtedness|Company Long-Term Liabilities LPTX (Leap Therapeutics, Inc.)|Amount of Long-Term Liabilities INTS|Company Long-Term Debts SNSE (Sensei Biotherapeutics, Inc.)|Company Long-Term Loans and Borrowings TOVX|Gritstone Bio - Company Long-Term Debts|Long-Term Debt Kineta Inc|NexImmune Corp (NEXI) - Company Long-Term Debt|Turnstone Biologics Corp. - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts harpoontx.com